Stifel Nicolaus Remains a Hold on VistaGen Therapeutics (VTGN)
TipRanks (Mon, 6-Jul 1:55 AM ET)
VistaGen Therapeutics (VTGN) Receives a Rating Update from a Top Analyst
TipRanks (Wed, 1-Jul 3:55 AM ET)
Business Wire (Tue, 30-Jun 8:00 AM ET)
Vistagen Advances Three Key Neuro Programs and Strengthens R&D Despite Increased Net Loss
Market Chameleon (Tue, 16-Jun 7:11 AM ET)
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Business Wire (Mon, 15-Jun 4:30 PM ET)
Business Wire (Tue, 9-Jun 8:30 AM ET)
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
PRNewswire (Mon, 1-Jun 2:40 PM ET)
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference
Business Wire (Wed, 27-May 8:30 AM ET)
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
Business Wire (Tue, 19-May 8:30 AM ET)
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
Business Wire (Thu, 14-May 8:30 AM ET)
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
Vistagen Therapeutics trades on the NASDAQ stock market under the symbol VTGN.
As of July 6, 2026, VTGN stock price was flat at $0.25 with 3,358,801 million shares trading.
VTGN has a beta of -0.48, meaning it tends to be less sensitive to market movements. VTGN has a correlation of 0.00 to the broad based SPY ETF.
VTGN has a market cap of $10.09 million. This is considered a Sub-Micro Cap stock.
Last quarter Vistagen Therapeutics reported $465,000 in Revenue and -$.37 earnings per share. This beat revenue expectation by $145,000 and missed earnings estimates by -$.07.
In the last 3 years, VTGN traded as high as $24.71 and as low as $.20.
The top ETF exchange traded funds that VTGN belongs to (by Net Assets): VTI, VXF, PSIL.
VTGN has underperformed the market in the last year with a price return of -88.0% while the SPY ETF gained +22.3%. VTGN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -58.1% and -63.3%, respectively, while the SPY returned +14.8% and +0.6%, respectively.
VTGN support price is $.23 and resistance is $.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VTGN shares will trade within this expected range on the day.
